Is Longevity a $1.2 Quadrillion Opportunity?
Inside the healthspan revolution and the technologies, companies, and breakthroughs driving it
Today I’m releasing the updated 2026 edition of my Longevity Metatrend Report, and a lot has changed since the first edition. I believe access to information like this is crucial, so I've decided to make this report available at no cost.
Since that first report published last year, the world’s first partial epigenetic reprogramming therapies have entered human clinical trials, AI-engineered proteins have achieved a greater than 50-fold improvement in the performance of key cellular reprogramming factors, the first genetically engineered pig organs have been successfully transplanted into living human patients, and wearable health platforms have surpassed $10 billion valuations. This field is no longer just promising. It is delivering.
The updated report is over 200 pages and covers everything from leading U.S. and international longevity centers, to direct-to-consumer health platforms, to the cutting-edge science of epigenetic reprogramming, immune system optimization, and organ regrowth, including profiles of over 40 companies and centers shaping the decade ahead.
Below, I’m sharing my Opening Thoughts from the report to give you a window into what’s inside.
MY OPENING THOUGHTS
There is no greater wealth than your health, and no greater gift science can offer humanity than an expanded healthspan. What would you do with an extra 50 years of health? How would it change your mindset about the future?
Longevity (more specifically, healthspan extension) is also the largest business opportunity emerging over the next decade. ARK Invest’s Big Ideas 2026 report projects that using quality-adjusted life years valued at $100,000 each, the total addressable market for longevity interventions reaches $1.2 quadrillion. The current global biotech market captures only ~0.1% of this potential.
Since 2012, I’ve immersed myself in the field, investing in and building companies, and devouring publications in biotech, nutrition, exercise, sleep, and AI. I’ve also had the opportunity to interview and learn from top scientists on my own Moonshots podcast, and on my stages at the Abundance Summit and my Abundance Longevity Trips.
The content of this Metatrend Report also stems from my work with dozens of top scientists and physicians with whom I’ve had the honor to start companies, and/or invested in their companies. The list is long, but here’s a top-level summary: Life Biosciences, Fountain Life, Lifeforce, Celularity, Lila Sciences, Insilico Medicine, Colossal Biosciences, Retro and NewLimit just to name a few.
I’ve also been a benefactor supporting the extraordinary work of giants in the field such as David Sinclair, PhD, George Church, PhD, the scientists at the Buck Institute, and the $101M Healthspan XPRIZE. These friends and co-conspirators have offered me a courtside seat into the speed at which this field is making progress.
The aim of this Longevity Metatrend Report is twofold: First, to offer a deep understanding of the current technologies, services, and companies delivering longevity services and leading research. And second, to offer a vision of where the longevity field is heading over the decade ahead.
This updated 2026 edition delivers significantly updated content in the realm of AI and wearables, as well as an update to company profiles reflecting the remarkable pace of progress over the past year. This report is not exhaustive by any means. My goal here remains to offer a top-level understanding of the field. It is worth noting that this report is biased towards U.S.-based services, but identifies, where possible, leaders outside the U.S. as well.
How Long Might We Live?
So, how long might we all live? That’s a question of significant debate, with those who laugh at targets of 120 or 150 years old, and those who believe there is no upper limit.
When I was in medical school in the late 1980s, I watched a documentary on the topic of “long-lived sea life” and learned that bowhead whales can live for 200 years, and the Greenland shark has an impressive lifespan of 400 to 500 years. I remember thinking, if they can live that long, why can’t we? My answer? “It’s either a hardware or a software problem, and we’re eventually going to be able to fix that.”
I believe that this is the decade that we conquer those hardware and software challenges, and we are in the midst of the healthspan revolution with the potential to hit “Longevity Escape Velocity” (LEV) by 2033. (This is Ray Kurzweil’s prediction, more on this shortly.)
Since the first edition of this report, the world’s first partial epigenetic reprogramming therapies have entered human clinical trials, AI-engineered proteins have achieved a greater than 50-fold improvement in the performance of key cellular reprogramming factors, the first genetically engineered pig organs have been successfully transplanted into living human patients, and wearable health platforms have surpassed $10 billion valuations built on longevity and healthspan metrics. The converging exponential technologies (AI, sensors, gene therapy, cellular medicine, and single-cell sequencing) are no longer just promising. They are delivering.
The Greatest Business Opportunity of this Decade
And make no mistake, this represents perhaps one of the greatest business opportunities of our lifetime. A groundbreaking study published in Nature Aging titled “The Economic Value of Targeting Aging” by researchers from London Business School, Harvard Medical School, and University of Oxford quantifies this opportunity in extraordinary terms.
“A slowdown in aging that increases life expectancy by 1 year is worth US$38 trillion, and by 10 years, US$367 trillion.”
This massive value proposition explains why visionary billionaires are pouring unprecedented capital into the space: Jeff Bezos and Yuri Milner backing Altos Labs, Coinbase CEO Brian Armstrong co-founding NewLimit, and OpenAI’s Sam Altman investing in Retro Biosciences. They recognize what I’ve long believed: in success, healthspan extension, alongside AI, will be the most valuable and impactful business on Earth.
And they’re no longer alone. Since the first edition of this report, the capital flowing into longevity has surged: Retro Biosciences raised $1 billion to advance its anti-aging research; Lila Sciences, building autonomous AI “science factories” for drug discovery, raised $550 million; NewLimit’s funding has grown to over $280 million; and wearable health companies WHOOP and Oura have each surpassed $10 billion valuations.
Meanwhile, pharmaceutical giants are committing billions to longevity-adjacent acquisitions and AI-powered drug discovery partnerships. The investment thesis is becoming consensus.
After all, how much would anyone pay for an extra 20, 30 or 50 years of vibrant health towards the end of their life?
For the first time in history, the intelligence applied to solving the problems of human aging is itself growing: compounding with every experiment, every dataset, every clinical milestone. And the implications are extraordinary.
I hope you enjoy this updated Metatrend Report and are preparing for a future where our greatest wealth is our health, and the gift of extended healthspan becomes accessible to all of humanity.
Best wishes,
Peter H. Diamandis, MD
READ THE FULL REPORT
The complete Longevity Metatrend Report is over 200 pages: profiling 40+ companies and centers across longevity diagnostics, DTC wellness, wearables, stem cell therapy, epigenetic reprogramming, immune system optimization, organ regrowth, and the $101M XPRIZE Healthspan. To make a report of this depth easy to read and navigate, we’ve built a dedicated interactive reading experience for it.
Access the Full Longevity Metatrend Report Here
More From Peter
If you’ve enjoyed Metatrends, here are more ways to stay connected:
Fascinating topic, akin to me wondering if one day we will also be able to engineer or set parameters for not just when we die but how- peacefully in our sleep, doing what we love, making sure we don't linger in pain, unable to communicate. A truly "advance directive."
The $1.2 quadrillion TAM is the number that will get quoted everywhere and its worth pressure-testing because it determines wether longevity is the greatest investment opportunity of the century or the greatest mislabelling of consumer surplus as addressable revenue.
ARK's methodology values quality-adjusted life years at $100K each. Thats a valid way to calculate the total economic value of longer healthier lives. But TAM in the venture capital sense means capturable revenue, and you cant capture consumer surplus as revenue unless you can charge people $100K per additional healthy year and have them pay it. Most people would pay significantly less than that, which means the investable market is a fraction of the headline number. The question is what fraction and the answer depends entirely on the cost curve.
This is where the AI convergence you describe becomes the most important variable in the entire thesis. If AI-engineered proteins achieve 50x improvments in cellular reprogramming factors as you report, and if autonomous drug discovery platforms like Lila Sciences compress the R&D timeline from decades to years, the cost of longevity interventions follows the solar panel trajectory: expensive at inception, rapidly declining through technological learning curves, eventually cheap enough for mass adoption. In that scenario the TAM genuinley approaches something extraordinary because the addressable population expands from billionaires to the entire middle class within 15-20 years.
The alternative trajectory is the luxury goods curve. Interventions stay expensive because the R&D costs are high, the regulatory pathway is slow, and the companies are incentivised to maintain premium pricing because their initial customer base can afford it. In that scenario longevity becomes a permanent advantage for the wealthy rather than a universal human advancement and the investable market caps out at maybe $50-100B annualy. Still enormous. Not $1.2 quadrillion.
The Retro Biosciences $1B raise and the NewLimit $280M are both priced for the solar panel trajectory. If theyre right and the cost curve bends the way it did for genomic sequencing, which went from $3 billion per genome to under $200 in twenty years, then the companies entering clinical trials now are positioned at the start of the steepest value creation curve in medical history. If the cost curve follows the pharmaceutical trajectory instead, where drugs stay expensive behind patent walls for 20 years, the returns are still good but the transformative TAM doesnt materialise.
The bowhead whale observation from medical school is the most effective framing in the piece by the way. 200-year lifespans already exist in nature. The question isnt wether radical healthspan extension is biologicaly possible. Its wether we can engineer the mechanism and price it for mass adoption within a single generation.